Other targets of MIR296 are the proto-oncogenes AKT2 in pancreatic cancer (Li et al., 2017), PLK1 in non-small cell lung cancer (Xu et al., 2016), SP1 in cervical cancer (Lv and Wang, 2018) and CDX1 in gastric cancer (Li et al., 2014). This evidence concerns the gene CDX1 and pancreatic neoplasm.